Видео ютуба по тегу Biotech M&A

JPMorgan Sees Pharma M&A ‘Very Active,’ But ‘Different’ in 2020
JPMorgan Sees Pharma M&A ‘Very Active,’ But ‘Different’ in 2020
A Follow-Up Visit with the Doctor | August 2024 Biotech Market Insights with Mark Charest, PhD
A Follow-Up Visit with the Doctor | August 2024 Biotech Market Insights with Mark Charest, PhD
План выкупа биотехнологической компании | Как акции подскочили на 50–2100% в результате слияний и...
План выкупа биотехнологической компании | Как акции подскочили на 50–2100% в результате слияний и...
Прогноз по сектору здравоохранения: во второй половине года активность в сфере слияний и поглощен...
Прогноз по сектору здравоохранения: во второй половине года активность в сфере слияний и поглощен...
🌄 Burning Man, 5 IPOs, 3 M&A's and biotech with Allan Gobbs, Co-Founder & Partner at Atem Capital
🌄 Burning Man, 5 IPOs, 3 M&A's and biotech with Allan Gobbs, Co-Founder & Partner at Atem Capital
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point? - Season 2 Episode 8
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point? - Season 2 Episode 8
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
Mizuho's Jared Holz details potential biotech, pharma acquisitions
Mizuho's Jared Holz details potential biotech, pharma acquisitions
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
Leading with science: A deep dive on biotech
Leading with science: A deep dive on biotech
💰 𝗣𝗛𝗔𝗥𝗠𝗔-𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗗𝗘𝗔𝗟𝗠𝗔𝗞𝗜𝗡𝗚 𝟮𝟬𝟮𝟱 𝗦𝗨𝗥𝗚𝗘 & 𝗧𝗢𝗣 𝗖𝗟𝗜𝗡𝗜𝗖𝗔𝗟 𝗧𝗥𝗜𝗔𝗟 𝗗𝗘𝗦𝗧𝗜𝗡𝗔𝗧𝗜𝗢𝗡𝗦
💰 𝗣𝗛𝗔𝗥𝗠𝗔-𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗗𝗘𝗔𝗟𝗠𝗔𝗞𝗜𝗡𝗚 𝟮𝟬𝟮𝟱 𝗦𝗨𝗥𝗚𝗘 & 𝗧𝗢𝗣 𝗖𝗟𝗜𝗡𝗜𝗖𝗔𝗟 𝗧𝗥𝗜𝗔𝗟 𝗗𝗘𝗦𝗧𝗜𝗡𝗔𝗧𝗜𝗢𝗡𝗦
The Deal -- Sector Review & Outlook: Biotech
The Deal -- Sector Review & Outlook: Biotech
M&A deals hit 20-year low in first half of 2025: Mergermarket
M&A deals hit 20-year low in first half of 2025: Mergermarket
💊🚀 𝗧𝗢𝗣 𝗦𝗜𝗡𝗚𝗟𝗘-𝗗𝗥𝗨𝗚 𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗙𝗜𝗥𝗠𝗦 & 𝗠&𝗔 𝗧𝗥𝗘𝗡𝗗𝗦 𝗥𝗘𝗦𝗛𝗔𝗣𝗜𝗡𝗚 𝗣𝗛𝗔𝗥𝗠𝗔 (𝟮𝟬𝟮𝟱–𝟮𝟬𝟮𝟳)
💊🚀 𝗧𝗢𝗣 𝗦𝗜𝗡𝗚𝗟𝗘-𝗗𝗥𝗨𝗚 𝗕𝗜𝗢𝗧𝗘𝗖𝗛 𝗙𝗜𝗥𝗠𝗦 & 𝗠&𝗔 𝗧𝗥𝗘𝗡𝗗𝗦 𝗥𝗘𝗦𝗛𝗔𝗣𝗜𝗡𝗚 𝗣𝗛𝗔𝗥𝗠𝗔 (𝟮𝟬𝟮𝟱–𝟮𝟬𝟮𝟳)
По словам Хольца из Oppenheimer, направление слияний и поглощений в биотехнологиях очень и очень обширно.
По словам Хольца из Oppenheimer, направление слияний и поглощений в биотехнологиях очень и очень обширно.
Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
Where Biotech is Headed Next: Wall Street’s Top Analysts Speak
Where Biotech is Headed Next: Wall Street’s Top Analysts Speak
Ажиотаж вокруг поглощения Metsera (MTSR): начинается битва Pfizer против Novo против Lilly
Ажиотаж вокруг поглощения Metsera (MTSR): начинается битва Pfizer против Novo против Lilly
Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
Bernstein's Ronny Gal on mergers in the biotech space
Bernstein's Ronny Gal on mergers in the biotech space
Biotech royalty deals on the rise and here to stay
Biotech royalty deals on the rise and here to stay
A Targeted ETF to Capture M&A, Consolidation in the Biotech Space
A Targeted ETF to Capture M&A, Consolidation in the Biotech Space